TipRanksStock Market NewsAUPH NewsCowen & Co. Thinks Aurinia Pharmaceuticals’ Stock is Going to Recover

Cowen & Co. Thinks Aurinia Pharmaceuticals’ Stock is Going to Recover

Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on Aurinia Pharmaceuticals (AUPHResearch Report) on April 25 and set a price target of $30.00. The company’s shares closed last Thursday at $10.85, close to its 52-week low of $9.70.

According to TipRanks.com, Cacciatore is a 1-star analyst with an average return of -1.2% and a 40.2% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Jazz Pharmaceuticals, and Aerie Pharma.

Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $24.44, implying an 116.5% upside from current levels. In a report issued on April 28, RBC Capital also maintained a Buy rating on the stock with a $22.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $33.97 and a one-year low of $9.70. Currently, Aurinia Pharmaceuticals has an average volume of 2.81M.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AUPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Read More on AUPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More